Monogenic mutations in the SHANK3 gene, which encodes a postsynaptic scaffold protein, play a causative role in autism spectrum disorder (ASD). Although a number of mouse models with Shank3 mutations have been valuable for investigating the pathogenesis of ASD, species-dependent differences in behaviors and brain structures post considerable challenges to use small animals to model ASD and to translate experimental therapeutics to the clinic. We have used clustered regularly interspersed short palindromic repeat/CRISPR-associated nuclease 9 to generate a cynomolgus monkey model by disrupting SHANK3 at exons 6 and 12. Analysis of the live mutant monkey revealed the core behavioral abnormalities of ASD, including
Introduction
Mutations in SHANK3 gene, which encodes a scaffolding protein in the postsynaptic density of excitatory synapses, contribute to approximately 1-2% of autism spectrum disorder (ASD) cases (1) (2) (3) (4) . SHANK3 also plays a key role in the clinical presentations of Phelan-McDermid syndrome, a chromosome 22q13.3 deletion syndrome (5) . Haploinsufficiency of SHANK3 is thought to be the mechanism responsible for the frequent presentation of ASD and other neurological comorbidity. Because of the wellestablished connection of SHANK3 to the synaptic development and function, SHANK3 causing ASD offers one of the best opportunities to model human ASD in model organisms.
Mutations in SHANK3 have been introduced and characterized in Drosophila, zebrafish, mouse and rat. Remarkably, a total of 14 lines of SHANK3 mutant mice have been reported (2, 4) . Analyses of these Shank3 isoform or complete knock-out mutant mice have offered many novel insights regarding the role of SHANK3 in synapses and the pathophysiology caused by SHANK3 mutations. However, one of notable findings is that, in contrast to severe clinical presentation in humans with heterozygous SHANK3 mutations, there is no or only very mild phenotypes in heterozygous Shank3 mutant mice (2, 4, 6) . This observation indicates that differences between human and rodent brains influence their response to the deficiency of SHANK3 protein. Indeed, our recent report has discovered that SHANK3 protein is the most abundant in the prefrontal cortex (PFC) in monkey but is expressed at the highest level in striatum (Str) in mice (4, 7, 8) . Furthermore, it has been well recognized that replication or translation of the therapeutic effects on rodent models to human clinical trials is often difficult (9, 10) . While there are many contributing factors for this difficulty, one of frequently debated subjects is whether an alternative model closer to human is needed for a preclinical study before launching an expensive clinical trial. Given those differences described, the importance of using non-human primates to model human diseases, especially psychiatric disorders, is clear.
We recently used clustered regularly interspersed short palindromic repeat (CRISPR)/CRISPR-associated nuclease 9 (Cas9) to disrupt exons 6 and 12 of SHANK3 gene in cynomolgus monkeys (8) . Our recent studies found that the complete loss of SHANK3 in the PFC results in a significant neuronal loss which probably leads to the observed late embryonic lethality (8) . However, one male monkey with a 2 bp deletion in exon 12 of SHANK3 (SHANK3 M3 ) has lived for 26 months now. Longitudinal investigation over the last 2 years revealed that the SHANK3
M3
monkey developed the core features of behavioral phenotypes of ASD, including impaired social interaction and apparent stereotypical locomotion. Furthermore, after treatment with fluoxetine, a selective serotonin reuptake inhibitor commonly prescribed for major depression and obsessive-compulsive disorder (OCD) (11) , the impaired social interaction and stereotypical behaviors were markedly improved. Thus, by generation of SHANK3 mutant monkey, we demonstrate that the non-human primate could faithfully recapitulate ASD-like behaviors, which holds a great potential for the development of effective therapeutics for ASD.
Results

Delayed growth and vocalization in SHANK3 mutant monkey
In our previous study, we used the Cas9/sgRNA method to target exons 6 and 12 of SHANK3 in cynomolgus monkeys (Macaca fascicularis), which resulted in different mutations including a large deletion (11 456 bp) and small indels of −2, −5, −8, −22 and +1 bp in the SHANK3 gene (8) . We observed a higher than expected embryonic and perinatal lethality associated with SHANK3 targeting, suggesting that SHANK3 is important for early development in primates. Nevertheless, we obtained a single male cynomolgus monkey (SHANK3 M3 ) that carries a 2 bp deletion in peripheral tissues (8) and has survived for 26 months up to now. Due to the mosaic nature of CRISPR/Cas9-mediated mutations and the lack of brain samples, the exact nature and extent of SHANK3 mutation in the brain of SHANK3 M3 monkey remain to be determined. We examined the behaviors of SHANK3 M3 monkey longitudinally after birth but more extensively after 12 months of age when abnormal behaviors started to emerge. Although the fact of a single mutant monkey and the choice of control have posed a challenge for the experimental design, we believe that a longitudinal and repeated study of behavioral phenotypes could still offer valuable data as described in other behavioral studies using non-human primates (12, 13) and case reports of human patients. Three age-and gender-matched (male) monkeys were used as controls, and all the monkeys for examination were housed in the same facility under the same living conditions. Newborn monkeys were kept together with mothers until 12 months of age. The first noticeable difference was that SHANK3 M3 monkey did not vocalize until 18 months, whereas three control monkeys did so immediately after birth (Fig. 1A) . The delayed vocalization in mutant monkey may be analogous to the delayed or no speech phenotype in young patients carrying SHANK3 mutations (14, 15) . We measured the growth parameters every 6 months after birth. The body weight and body length of SHANK3 M3 monkey were significantly smaller and shorter, respectively, than those of control monkeys (Fig. 1B-D) . However, the head circumference of SHANK3 M3 monkey is comparable to the controls (Fig. 1E) .
No other behavioral difference between SHANK3 M3 monkey and controls was noticed before they became one year old. We also noted enamel dysplasia, which had been reported in some autistic children with SHANK3 mutations (16), in SHANK3 M3 monkey (Fig. 1F ).
Repetitive and anxiety-like behaviors in SHANK3 mutant monkey
Video recording of daily activity is considered a simple and effective method to assess the behaviors of monkeys (17) . We assessed the activity of monkeys in the home cage and the adaptability in a new cage using video recording of two halfhour daily sessions for six consecutive days. The behaviors were scored by three trained experimenters unaware of animal identity. Compared with control monkeys, SHANK3 M3 monkey exhibited significant stereotypic and anxiety-like behaviors in both home and new cages, which is evident by more frequent circling behavior (Supplementary Material, Video S1). This typical behavior has been reported to associate with anxiety in non-human primates (18, 19 Ctrl1 0.00 ± 0.00 min, * * P = 0.0085; Ctrl2 1.78 ± 0.87 min, * P = 0.0172; Ctrl3 7.58 ± 1.52 min, P = 0.1931) and the novel cage (SHANK3 M3 9.08 ± 1.50 min, Ctrl1 0.91 ± 0.49 min, * * P = 0.0065; Ctrl2 0.97 ± 0.83 min, * * P = 0.0019; Ctrl3 0.23 ± 0.08 min, * * P = 0.002; Fig. 2B ).
Crook-tail is a behavior that also associates with anxiety or fearfulness in a juvenile monkey (20 Fig. 2D ). The mutant monkey also exhibited significantly high frequency of crooktail in the home cage (SHANK3 M3 15.17 ± 2.89, Ctrl1 1 ± 0.37, * P = 0.0117; Ctrl2 0.83 ± 0.31, * * P = 0.0088; Ctrl3 0.5 ± 0.34, * * P = 0.0090) and the novel cage (SHANK3 M3 26.83 ± 11.54, Ctrl1
2.5 ± 0.76, * * P = 0.0074; Ctrl2 2.3 ± 0.42, * * P = 0.0070; Ctrl3 2.56 ± 0.73, * * P = 0.0078; Fig. 2E ).
Impaired social interaction in SHANK3 mutant monkey
We next examined social interaction by performing a one-toone interaction test using a protocol previously described (21) , in which one monkey (SHANK3 M3 or its age-and gender-matched control monkey) was paired with a sociable wild-type monkey. A sociable monkey was selected based on its frequent interactions with others (22) . examined. The data are presented as mean ± SEM. NS, * P < 0.05, * * P < 0.01, Mann-Whitney U test. (F) The frequency and (G) duration of active social interaction, passive social interaction and stereotypical behaviors when a test monkey of SHANK3 M3 or wild-type control was paired with a sociable monkey. Data are analyzed by one-way ANOVA and presented as mean ± SEM. NS, * P < 0.05; * * P < 0.01; * * * P < 0.001; * * * * P < 0.0001. See detailed statistic results in the text.
13.41 ± 1.19 min, * * * * P < 0.0001; Ctrl3 10.83 ± 2.05 min, * P = 0.0105) than each control monkey. Instead, SHANK3
M3
monkey displayed a greater frequency (SHANK3 M3 41.5 ± 6.3, Ctrl1 5.5 ± 5.5, * * P = 0.0016; Ctrl2 0 ± 0, * * * * P < 0.0001; Ctrl3 1.33 ± 1.15, * * P = 0.0012; Fig. 2F ) and longer duration (SHANK3 
Reduced eye contact in SHANK3 mutant monkey
Eye contact is considered to be essential for communication and social interaction in both humans and other primate species (17, 23 35.67 ± 3.148, * * P = 0.0045; Ctrl2 35.33 ± 5.364, * * * P = 0.0004; Ctrl3 43.83 ± 11.44, * * * P = 0.0001; Fig. 3B ). Instead, the mutant monkey showed intense anxiety and fear by frequently circling in the cage (Supplementary Material, Video S4).
Reduced brain activity in SHANK3 mutant brain
Positron emission computed tomography (PET) is a noninvasive in vivo molecular imaging technique that is widely used in clinical diagnosis and treatment evaluation (24) (25) (26) Regional SUVr values in different brain regions in control (n = 3) and SHANK3 M3 monkeys. Data were obtained from three PET-MRI imaging tests, presented as mean ± SEM and are analyzed by two-way ANOVA. NS, * P < 0.05, * * P < 0.01, * * * P < 0.001, * * * * P < 0. Figure 3C and D, using pons (Pon) as the reference region (27, 28) , we observed that the regional brain standardized uptake value ratio (SUVr) values for SHANK3 were specifically reduced in a variety of brain regions when compared with the control [cerebellum (CB) SHANK3 M3 1.60 ± 0.31, P = 0.32; Ctrl2 2.85 ± 1.05, P = 0.99; Ctrl3 2.57 ± 0.79, P = 0.98). In addition, fluoxetine treatment alleviated stereotypical behavior by reducing its duration (SHANK3 M3 0.14 ± 0.06; Ctrl1 0.93 ± 0.05, * * * P = 0.004; Ctrl2 1.0 ± 0.0, * * * P = 0.0001; Ctrl3 0.90 ± 0.09, * * P = 0.0017) and frequency (SHANK3 M3 0.05 ± 0.02; Ctrl1 0.78 ± 0.14, * P = 0.0112; Ctrl2 1.0 ± 0.0, * * * * P < 0.0001; Ctrl3 0.88 ± 0.12, * * P = 0.0026; Fig. 4C ). Moreover, fluoxetine treatment increased eye contact duration (SHANK3 M3 3.41 ± 1.04; Ctrl1 0.65 ± 0.07, * * P = 0.004; Ctrl2 1.07 ± 0.11, * P = 0.0148; Ctrl3 0.60 ± 0.07, * * P = 0.0034) and frequency of SHANK3 M3 monkey (SHANK3 M3 4.55 ± 0.79; Ctrl1 0.88 ± 0.16, * P = 0.0247; Ctrl2
1.21 ± 0.17, * P = 0.0201; Ctrl3 0.91 ± 0.11, * P = 0.0219; Fig. 4D 
Discussion
ASD represents one of the most important and common neurodevelopmental and neuropsychiatric diseases. Accordingly, there are considerable research efforts to tackle ASD from many different aspects. However, our understanding of the pathogenesis of ASD remains poor, and the effective treatment of ASD remains to be developed. These is an apparent question of whether many currently well-studied rodent models are sufficient to model the complex social behavior associated with ASD (34, 35) . SHANK3 mutant monkeys generated by us (8) and other recently established MECP2 mutant monkeys using transgenic or TALEN-mediated methods (21, 36) have demonstrated the value of genetically modified non-human primate models for ASD research.
Using the CRISPR/Cas9-mediated genetic manipulation, we obtained a live mutant monkey that carries a 2 bp deletion in exon 12 of the SHANK3 gene. This mutation is predicted to result in a frameshift at Q419 (Q419fsX486) between ANK and SH3 domains for the majority of SHANK3 isoforms. It should be noted that a single base-pair insertion in an autism patient (37) , which leads to a premature stop codon at the residue 503 (A447fsX503), is close to the 2 bp deletion of SHANK3 M3 monkey.
Because we were unable to analyze the brain tissues of this live SHANK3 M3 monkey, we could not determine the SHANK3 mutation types and mosaicism in its brain. However, the robust core features of ASD and abnormal brain activity in SHANK3
M3
monkey lend the support for SHANK3 haploinsufficiency, which is well established in ASD patients with SHANK3 mutations (3, 15 Data are presented as mean ± SEM (n = 3 for control for comparing to SHANK3 M3 monkey) and analyzed by one-way ANOVA. * P < 0.05, * * P < 0.01, * * * P < 0.001, * * * * P < 0.0001.
no behavioral phenotypes of Shank3 heterozygous mutant mice (6) . Similarly, the circling behavior of SHANK3 M3 monkey in cage is apparent and reproducible. The robust behavioral phenotypes of SHANK3 M3 monkey strongly indicate that the non-human primate offers a good alternative to model ASD. Despite the similarity in the phenotypes of the SHANK3 M3 monkey, there are some nontrivial caveats that need to be considered and discussed. First, our findings are based on the results from one mutant monkey. Due to the lower than expected rate of newborn SHANK3 mutant monkeys and the critical function of SHANK3 for early development of the monkey brain (8) , it is difficult to obtain a large number of live founder animals by CRISPR/Cas9 gene editing. In addition, the genotype and phenotype correlation in humans has not been firmly established because of molecular heterogeneity of SHANK3 mutations (3, 15) . Thus, it is expected to see a wide range of behavioral phenotypes in individual CRISPR/Cas9-targeted monkeys if their mutations are not identical. In the future, non-human primate cloning technique may facilitate the generation of monkeys with the same genetic modification (39) . While it is reasonable to be cautious in drawing a conclusion from a single case study, like other typical case studies in clinic, our longitudinal observational studies presented here provided clear evidence for the abnormal behaviors in SHANK3 M3 monkey.
From the studies of SHANK3 in both rodent and non-human primate models, we have observed clear and significant differences among them. In humans, there are no reports on any case with homozygous SHANK3 mutation, but patients with heterozygous SHANK3 mutation are typically severely affected. In rodents, a complete depletion of Shank3 in homozygotes does not affect the survival and early development. Heterozygotes of Shank3 mutant mice show very mild or no abnormal behavioral phenotypes (6) . In contrast, the complete depletion of the SHANK3 gene in the certain monkey brain region results in significant neuronal loss and late embryonic lethality (8) . This may suggest that complete loss of SHANK3 in human is likely early lethal, and the live SHANK3 mutant monkey is more likely to have a partial loss or haploinsufficiency of SHANK3.
Our findings also demonstrate that the ASD-like symptoms in SHANK3 mutant monkey can be effectively alleviated by the treatment with the antidepressant fluoxetine. Fluoxetine is a member of the class of selective serotonin reuptake inhibitors drug commonly prescribed as an antidepressant. Empirically, many clinicians prescribe fluoxetine to treat repetitive behaviors in ASD children, including SHANK3 mutation-causing ASD (Joan Jasien, personal communication). In a small scale of double-blind placebo-controlled fluoxetine trial, Holland et al. (32) reported a significant improvement for repetitive behavior in adult individuals with ASD. Although the mechanism underlying the efficacy of fluoxetine treatment in SHANK3 M3 monkey remains to be investigated, the strong response to fluoxetine treatment provides the first example that the non-human primate model may be valuable for future drug development of ASD.
Materials and Methods
Animals
SHANK3
M3 monkey and age-and gender-matched healthy control cynomolgus monkeys (M. fascicularis) were housed in cages and examined for their behaviors at Guangdong Landau Biotechnology Co. Ltd., which is an Association for Assessment and Accreditation of Laboratory Animal Care-accredited facility. All animal-related protocols were approved in advance by the Insti- 
Measurement of physical characteristics
Body weight, length and head circumference of SHANK3 M3 monkey and 15 age-and gender-matched control monkeys, which were housed in the same condition, were measured at the first day of every 6 months.
Behavioral observations
Direct observation or recording of monkey behaviors when they were housed individually was performed following previously published protocols (40) . SHANK3 M3 monkey and three ageand gender-matched control monkeys were observed in both the home cage (L60 × W70 × H80 cm) and the novel cage (L120 × W85 × H140 cm) to assess solo behavioral manifestations in the absence of social stimulation. The behavioral categories of inactivity, environment exploration and stereotypical behaviors were statistically analyzed. The inactivity is defined as not engaged in any behaviors with open or close eyes. The environment exploration is defined as a monkey manipulates objects in the cage with hands and/or mouth non-repetitively and investigates cage (searches, sniffs bars) (41) . The stereotypical behaviors are defined as repetitive and consistent actions with no apparent purposes, including pacing (repetitive, ritualized movement usually involving circling in the cage), self-grasping (grabbing or holding onto part of their own body), rocking (a back and forth movement of the upper body with still feet), bouncing (jumping up and down on all four legs) and cage shaking (any vigorous shaking of the cage) (41) . The tested monkeys were recorded twice daily (half an hour a section) at the same time of the day (0900-1130; 1400-1630) for six consecutive days.
Social interaction test
Social interaction test was performed in the set of one-to-one interaction using the previously reported protocol for monkeys (21) . SHANK3 M3 or its age-and gender-matched control monkey was paired with one wild-type sociable monkey, a monkey with good social skills and high tendency to interact with others (22) . The measured behaviors included active social interaction, passive social interaction, staying alone and stereotypical behaviors. Active social interaction is defined as initiating a play, sharing toys, grooming for others and sitting together (within another monkey's arms' reach or in contact), while passive social interaction is defined as receiving aforesaid social interactions from the sociable monkey. The monkey is considered as staying alone when there is no other monkey within its arms' reach. The stereotypical behaviors are defined earlier.
In our experiment, the tested monkeys were recorded once daily (half an hour a day) at the same time of the day (1400-1630) for six consecutive days. Each video recording was analyzed simultaneously by three trained observers unaware of animal identity. During the scoring, the observers recorded the frequency and duration of a specific behavior by manually starting and stopping the video under the condition that they all agreed on the classification of the observed behavior. The inter-observer correlation coefficient was found to be >0.90 after training by SPSS (Chicago, IL, USA) statistical analysis. The frequency and duration of each behavior were statistically compared between SHANK3 M3 and control monkeys.
Eye contact
Eye contact assay was carried largely following a previous protocol (17) . During the test, the experimenter familiar to the tested monkeys sat opposite the monkey at a 1 m distance, and the experimenter was directly looking at the monkey for 3 min per section, once a day (0900-1030), and each monkey was tested for six consecutive days. The monkeys' (SHANK3 M3 and three controls) responses were videotaped by a video camera that was positioned behind the experimenter. The frequency and duration of eye contact between the tested monkey and the experimenter were statistically analyzed.
PET-MR scan and imaging data process
We performed non-invasive multi-modality brain imaging study of with minimal ambient noise and light. After 50 min, the subject was immobilized with ketamine (10 mg/kg; i.m.), placed into the scanner in the supine position and maintained under anesthesia with 1-3% isoflurane and 98.4% oxygen. Head position was fixed with a stereotactic frame. CT scan was performed first, followed by eight-minute static positron emission data collection at 60 min post-injection. CT data were acquired in breath-hold with 140 kV, 230 mA modulated using the GE AutomA technique (GE Medical System, Milwaukee, USA) with a noise index of 30, slice thickness of 3.75 mm, slice interval of 3.27 mm, matrix size of 512 × 512 and scan FOV of 50 cm. PET data were acquired in 3-dimensional time-of-flight (TOF) mode with a slice thickness of 3.27 mm, slice interval of 3.75 mm, matrix size of 256 × 256 and scan FOV of 70 cm. The PET data were attenuation-corrected by the integrated CT attenuation-corrected (CTAC). The CT data were reconstructed in standard mode with display field of view (DFOV) of 30 cm and window width/window level of 100/45, advanced statistical iterative reconstruction 40%. The PET data were then reconstructed in terms of the point spread function together with TOF technology with DFOV of 30 cm. Data analysis was performed using PMOD 3.9 (Pmod Technologies LLC, Zürich, Switzerland). The co-registration of PET image to individual MR image, which was transformed into brain template MR images, was carried out following published protocols (26, 42) . Volume of interests were extracted from the CB, Str, Cau, Put, Amyg, Hip, Phg, Ltemp, DLPFC, PFC, ACC and Pon. The uptake of [ 18 F]FDG in Pon was used as reference for SUVr analysis as previously described (42) . Statistical analyses were performed with GraphPad Prism 6.0 (GraphPad Software, La Jolla, USA).
Fluoxetine treatment
Fluoxetine hydrochloride (20 mg/tablet, approved for human use; Patheon France), was grounded into powder and mixed with food for oral taking. The dosing regimen was chosen based on previous studies of fluoxetine in non-human primates and ASD patients (32, 33) . Over two-year-old monkeys (one mutant and three controls) were orally given fluoxetine hydrochloride for 2 weeks with a dosing began at 1.6 mg/kg/day for the first 3 days and adjusted to 2.5 mg/kg/day for the rest (11 days). Phenotypes, including stereotypical behaviors and eye contact, were examined daily 1 week after the drug administration for 2 weeks. Tested monkeys were recorded once daily (30 min a day) at the same time of the day (1400-1630) for six consecutive days.
Statistical analyses
Data analysis was conducted using the SPSS version 19.0 software package. The normality of the data was analyzed by Kolmogorov-Smirnov tests (Kolmogorov-Smirnov tests: P > 0.05).
All the data except the stereotypical behavior (frequencies: P = 0.002 and durations: P = 0.006) were normally distributed. One-way ANOVA was used to analyze the differences between the mutant and control monkeys in active social interaction, passive social interaction and staying alone. One-way ANOVA was used to perform all pairwise comparisons between the mutant and each control monkey. Mann-Whitney U tests were used to analyze the frequency and duration of stereotypical behavior. Regional brain SUVr data were analyzed by two-way ANOVA. The alpha level was set at P = 0.05 (not significant (NS), P > 0.05; * P < 0.05; * * P < 0.01; * * * P < 0.001; * * * * P < 0.0001). For body weight, body length and head circumference, statistical analyses were performed with GraphPad Prism 6.0 (www.graphpad.com). All P-values were generated using two-sided tests, and all the data were presented as the mean ± standard error of the mean (SEM).
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